(19)
(11) EP 3 634 998 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
09.04.2025 Bulletin 2025/15

(45) Mention of the grant of the patent:
26.02.2025 Bulletin 2025/09

(21) Application number: 18729644.7

(22) Date of filing: 04.06.2018
(51) International Patent Classification (IPC): 
C07K 16/18(2006.01)
C07K 16/28(2006.01)
 C07K 16/24(2006.01)
C07K 16/32(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2809; C07K 16/2866; C07K 16/32; C07K 2317/24; C07K 2317/31; C07K 2317/33; C07K 2317/567; C07K 2317/622; C07K 2317/626; C07K 2317/75; C07K 2317/92; C07K 2317/94
(86) International application number:
PCT/EP2018/064630
(87) International publication number:
WO 2018/224441 (13.12.2018 Gazette 2018/50)

(54)

ANTI-CD3 EPSILON ANTIBODIES

ANTI-CD3 EPSILON-ANTIKÖRPER

ANTICORPS ANTI CD3 EPSILON

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 05.06.2017 US 201762515293 P
27.11.2017 EP 17203832

(43) Date of publication of application:
15.04.2020 Bulletin 2020/16

(60) Divisional application:
25159929.6

(73) Proprietor: Numab Therapeutics AG
8810 Horgen (CH)

(72) Inventors:
  • GUNDE, Tea
    8005 Zurich (CH)
  • HESS, Christian
    8045 Zurich (CH)
  • MEYER, Sebastian
    5445 Eggenwil (CH)
  • SIMONIN, Alexandre
    68128 Rosenau (FR)
  • BELTRAMETTI, Teddy
    6467 Schattdorf (CH)
  • URECH, David
    8645 Jona (CH)

(74) Representative: Wallinger Ricker Schlotter Tostmann 
Patent- und Rechtsanwälte mbB Zweibrückenstraße 5-7
80331 München
80331 München (DE)


(56) References cited: : 
WO-A1-2015/063339
WO-A1-2016/020444
WO-A1-2016/184570
WO-A2-2010/037835
WO-A2-2016/014974
 WO-A1-2015/181098
WO-A1-2016/071355
WO-A1-2017/023761
WO-A2-2012/143524
   
  • ANDRES LOPEZ-ALBAITERO ET AL: "Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody", ONCOIMMUNOLOGY, vol. 6, no. 3, 4 March 2017 (2017-03-04), pages e1267891, XP055374515, DOI: 10.1080/2162402X.2016.1267891
  • BORTOLETTO NICOLA ET AL: "Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells", EUROPEAN JOURNAL OF IMMUNOLOGY,, vol. 32, no. 11, 1 November 2002 (2002-11-01), pages 3102 - 3107, XP002436763, ISSN: 0014-2980, DOI: 10.1002/1521-4141(200211)32:11<3102::AID-IMMU3102>3.0.CO;2-C
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).